AGM/EGMJun 3, 2026, 04:11 PM
Entera Bio Ltd. Announces 2026 Annual Meeting Agenda
AI Summary
Entera Bio Ltd. has filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders, scheduled for July 14, 2026. Key agenda items include the election of three Class III directors, approval of amended compensation terms for non-executive directors, and share-based compensation for specific directors and the CEO. Shareholders will also vote on amendments to the 2018 Equity Incentive Plan and the company's Articles of Association to increase authorized share capital. The appointment of Kesselman & Kesselman (PwC) as independent auditors for fiscal year 2026 is also on the agenda.
Key Highlights
- Entera Bio Ltd. to hold 2026 Annual Meeting of Shareholders on July 14, 2026.
- Shareholders to elect three Class III directors until 2029.
- Proposals include approving amended compensation for non-executive directors.
- Share-based compensation for directors Steven D. Rubin and Geno J. Germano to be voted on.
- One-time compensation grants for director Sean Ellis and CEO Miranda Toledano proposed.
- Amendment to 2018 Equity Incentive Plan to increase shares by 2,500,000.
- Increase in authorized share capital to be approved.
- Advisory resolution on named executive officers' compensation.
- Appointment of Kesselman & Kesselman (PwC) as independent auditors for FY2026.
Price Impact
More from ENTX